Pegunigalsidase alfa clinical trials
Also written PRX-102.
How each study uses pegunigalsidase alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pegunigalsidase alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 9 May 2023 · ELFABRIO · BLA 761161 (FDA, Drugs@FDA)
- European Union
- 4 May 2023 · Elfabrio · EMEA/H/C/005618 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Protalix (6) · Chiesi Farmaceutici S.p.A. (4)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test pegunigalsidase alfa, phase 3 first.
- Oct 2027Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry DiseasePhase 2/3 · Chiesi Farmaceutici S.p.A.
Studies
Open first, then newest update. How each study uses pegunigalsidase alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseaseRecruitingPhase 2/3Chiesi Farmaceutici S.p.A.NCT06328608Written as PRX-102 1 mg/kg every two weeksHow we know
- Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry DiseaseRecruitingPhase 2/3Chiesi Farmaceutici S.p.A.NCT05710692Written as PRX-102 1 mg/kg every 2 weeksHow we know
- Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease PatientsCompletedPhase 3Chiesi Farmaceutici S.p.A.NCT03614234Written as pegunigalsidase alfaHow we know
- Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry DiseaseCompletedPhase 3Chiesi Farmaceutici S.p.A.NCT03566017Written as pegunigalsidase alfaHow we know
- Extension Study of PRX-102 for up to 60 MonthsCompletedPhase 1/2ProtalixNCT01981720Written as PRX-102 (pegunigalsidase alfa)How we know
- Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal FunctionCompletedPhase 3ProtalixNCT02795676Written as PRX-102 (pegunigalsidase alfa)How we know
- Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)CompletedPhase 3ProtalixNCT03018730Written as PRX-102 (pegunigalsidase alfa)How we know
- Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 WeeksCompletedPhase 3ProtalixNCT03180840Written as Pegunigalsidase alfaHow we know
- Dose-ranging Study of PRX-102 in Adult Fabry Disease PatientsCompletedPhase 1/2ProtalixNCT01678898Written as PRX-102How we know
- Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry DiseaseWithdrawnPhase 3ProtalixNCT02921620Written as PRX-102How we know
Codes
What other systems call pegunigalsidase alfa · ClinicalTrials.gg INT002167
- MeSH (NLM) C000731937pegunigalsidase alfaOne source NLM
- UNII (FDA) 8M7V7Q6537PEGUNIGALSIDASE ALFAConfirmed FDA, NLM
- NCI Thesaurus C175187Pegunigalsidase AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731937 | pegunigalsidase alfa | One source NLM |
| UNII (FDA) | 8M7V7Q6537 | PEGUNIGALSIDASE ALFA | Confirmed FDA, NLM |
| NCI Thesaurus | C175187 | Pegunigalsidase Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.